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(CKD) and congestive heart failure (CHF). The objective of this study
was to investigate the impact of CM with different osmolality on
cardiac preload in patients with CKD and CHF.
METHODS 90 non-ST elevation acute coronary syndromes (NSTE-
ACS) patients with renal insufﬁciency (estimated glomerular ﬁltration
rate60 ml/min) and CHF were equally randomized to receive either
iodixanol 320 (Visipaque) or iopromide 370 (Ultravist) in PCI pro-
cesses. We applied pulse indicator continuous cardiac output (PICCO)
technology to observe the change of hemodynamic indexes in the
perioperative period. Contrast induced nephropathy (CIN) was
deﬁned as increase in serum creatinine 0.5 mg/dl or >25% from
baseline.
RESULTS Baseline characteristics were well-matched between the 2
groups. CIN developed in 21 patients (23.3%), and there was no sig-
niﬁcant difference between the iodixanol and iopromide groups (17.8%
vs. 28.9%, P¼0.213). Extravascular lung water index (EVLWI), global
end-diastolic index (GEDI) and central venous pressure (CVP) were
all signiﬁcantly increased after application of CM in the iopromide
group (13.13.8 ml/kg vs. 8.43.2 ml/kg in EVLWI; 1381472 ml/m2
vs. 962362 ml/m2 in GEDI; 145 mmHg vs. 115 mmHg in CVP; all
P<0.001), and the changes of these preload indexes in the iopromide
group were all signiﬁcantly greater than in the iodixanol group (all
P<0.05). The incidence of adverse events in terms of death, myocardial
infarction, repeat revascularization did not differ between the two
groups, but the incidence of acute heart failure in the iopromide group
was signiﬁcantly higher than the iodixanol group (P¼0.048).
CONCLUSIONS Iopromide could signiﬁcantly increase cardiac pre-
load in patients with CKD and CHF as compared to iso-osmolar CM
iodixanol, and this is associated with a higher occurrence of acute
heart failure event during the perioperative stage.
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Central Venous Pressure Guided Hydration Reduces Contrast Induced
Nephropathy in Patients Undergoing Coronary Procedures with Chronic
Kidney Disease and Congestive Heart Failure
Geng Qian, Feng Cao, Yundai Chen
Department of Cardiology, Chinese People’s Liberation Army General
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OBJECTIVES Patients at moderate or high risk for contrast induced
nephropathy (CIN) should receive sufﬁcient hydration before contrast
application to prevent CIN. The guidelines recommend controlling
rate of ﬂuid administration in patients with heart failure, but inade-
quate hydration markedly increases the incidence of CIN. We expect
to explore an individual hydration method for patients with conges-
tive heart failure (CHF) and chronic kidney disease (CKD) to reduce
the incidence of CIN and at the same time to avoid the acute heart
failure for these patients.
METHODS This prospective, randomized, double-blind, comparative
clinical trial enrolled 264 consecutive patients with CHF and CKD
undergoing coronary procedures. These patients randomly received
either central venous pressure (CVP) guided hydration (n¼132) or
standard intravenous isotonic saline hydration (control group; n¼132).
In the CVP guided group, hydration infusion rate was automatically
adjusted according to CVP level every hour, and both study groups
received intravenous ﬂuids for the same duration but at different
rates. CIN was deﬁned as an absolute increase in serum creatinine
(SCr) > 0.5 mg/dL (44.2 mmol/L) or a relative increase >25% compared
to baseline SCr. Adverse events were assessed by 3 months follow-up
and all such events were classiﬁed by staff who were masked to
treatment assignment. This trial is registered with ClinicalTrials.gov,
number NCT02405377.
RESULTS Baseline characteristics were well-matched between the
two groups. Mean baseline SCr and the predictive CIN risk score were
comparable in the two groups. The total mean volume of isotonic
saline administered in the CVP guided hydration group is signiﬁcantly
higher than the control group (1827497 vs. 1202247; p<0.001). CIN
occurred less frequently in CVP guided hydration group than in the
control group (15.9% vs. 29.5%; p¼0.006). The incidences of acute
heart failure (acute pulmonary edema) during the perioperative
period did not differ between the two groups (6.8% vs. 7.6%;
p¼0.500). A lower incidence of cumulative 90-day adverse events
(renal replacement therapy, acute myocardial infarction, acute heart
failure and death) was also observed in CVP guided hydration patients
than in controls (8.3% vs. 20.5%; p¼0.004).
CONCLUSIONS CVP guided ﬂuid administration can safely and
effectively reduce the risk of CIN for patients with CKD and CHF.GW26-e0451
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OBJECTIVES To investigate the long noncoding RNA (lncRNA)
NONHSAT112178 as a biomarker for coronary artery disease (CAD) in
peripheral blood monocyte cells (PBMC).
METHODS RT-qPCR was performed to validate the microarray results,
ROC curve was applied to study the potential of NONHSAT112178 as a
biomarker. Diagnostic models from NONHSAT112178 alone or combi-
nation of risk factors were constructed by Fisher criteria. The function
of NONHSAT112178 was conﬁrmed in THP-1 cell line by siRNA.
RESULTS The result indicated the expression of NONHSAT112178 in
PBMCs from CAD patients increased more than twice times by
microarray analysis and RT-qPCR compared with the control group,
P<0.05. Further validated independently in a population (2020),
NONHSAT112178 expression (about 2.2-fold in CAD patients), was
consistent with the result from lncRNA microarray. The predictive
value of NONHSAT112178 was assessed in a larger population of 211
CAD patients and 171 controls. Using a diagnostic model by Fisher
criteria, considered the risk factors, the corresponding optimal
sensitivity was increased from 70.00% to 82.00%, the speciﬁcity was
slightly decreased from 94.00% to 78.00%, respectively. AUC was
increased from 0.727 to 0.785 (P¼0.001), from 0.712 to 0.768
(P¼0.010), and from 0.769 to 0.835 (P¼0.069), in original, training and
test set, respectively. Moreover, in a prospective study, we found the
sensitivity of NONHSAT112178 was increased from 68.00% to 76.00%
and speciﬁcity was decreased from 90.00% to 82.50%, respectively.
NONHSAT112178 was also found to be speciﬁc in CAD compared with
other cardiovascular diseases. Finally, we found neighboring protein-
coding gene peroxisome proliferator-activated receptor delta
(PPARD), and its target genes adipose differentiation-related protein
(ADRP) and angiopoietin-like 4 (ANGPTL4) are all transrepressed by
NONHSAT112178.
CONCLUSIONS Our present study indicated that NONHSAT112178
with function, neighboring protein-coding gene PPARD, combination
of risk factors can be used as a biomarker for CAD.
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Guided Low-Dose Furosemide for Preventing Contrast-induced
Nephropathy in the Percutaneous Coronary Intervention
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OBJECTIVES This study was to evaluate on the prophylactic effect of
low-dose furosemide guided by left ventricular end-diastolic pressure
and brain natriuretic peptide on contrast-induced nephropathy of
patients with percutaneous coronary intervention on basis of
adequate hydration.
METHODS The patients of PCI(Percutaneous Coronary Intervention)
were recruited. The inclusion criteria: 1.male or female, 18-75 years
old; 2.sign the informed consent. Exclusion criteria: 1.inability to
obtain consent from participants; 2.primary percutaneous coronary
intervention for ST-segment elevation myocardial infarction; 3.renal
replacement therapy; 4.exposure to radiographic contrast media
within the previous 2 days; 5.allergy to radiographic contrast media;
6.acute decompensated heart failure; 7.severe valvular heart disease;
8.mechanical aortic prosthesis; 9.left ventricular thrombus; 10.history
of kidney or heart transplantation. The patients were divided into two
groups: the control group and experimental group, the basic charac-
teristics and routine examinations were recorded. All patients were
given standard hydration process according to the guideline, the
control group was administered 20 mg furosemide right after the
procedure, but the experimental group was treated individually, ac-
cording to the result of BNP(Brain Natriuretic Peptide) and LVEDP
(Left Ventricular End-Diastolic Pressure). Only the patients of
LVEDP15mmHg or BNP100pg/ml or BNP more than 50% of preop-
erative values were given 20 mg furosemide and the rest had no
special treatment. The creatinine was obtained before and 48h after
the PCI procedures, so the creatinine clearance rate and glomerular
ﬁltration rate could be calculated, also the all-cause mortality,
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incidence of cardiac adverse events were followed up at the time of 1
and 6 months.
RESULTS The designed number were 1140 patients, now it was the
results of 188 patients(the control group was 87 and experimental
group was 101). The basic clinical characteristics and complicated
disease were not signiﬁcantly different(P>0.05). The creatinine,
creatinine clearance rate and glomerular ﬁltration rate were not
signiﬁcantly different in control group before and after the oper-
ation(P¼0.823, P¼0.87 and P¼0.93). The same results were gained in
experimental group(P¼0.153, P¼0.16 and P¼0.21). There were no
difference of changing degree of creatinine, creatinine clearance rate
and glomerular ﬁltration rate before and after the PCI between the
control and experimental group (P¼0.398, P¼0.065 and P¼0.956). The
incidence of CIN in control group was 8.05%, and the incidence of CIN
in experimental group was only 2.97%, but there was no difference
also (P¼0.12).
CONCLUSIONS The primary results shows that the left ventricular
end-diastolic pressure and brain natriuretic peptide guided low-dose
furosemide may be beneﬁcial for preventing contrast-induced ne-
phropathy in the percutaneous coronary intervention, but the
conclusion need further observations to prove.
International Clinical Trials Register main ID: ChiCTR-IOR-14005250.
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Relationship between clopidogrel metabolism polymorphism and variable
platelet reactivity in 1 year: a cohort study
Wang Xiaodong, Yan Lai, Yu Luo, Jiani Tang, Zi Ye, Xuebo Liu
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OBJECTIVES To investigate the effect of clopidogrel polymorphism
on platelet reactivity and clinical outcome.
METHODS 236 PCI-treated patients were recruited and followed up
for one year in a cardiovascular monocenter. All blood samples of
patients were collected, and deoxyribonucleic acid (DNA) were gen-
otyped. Platelet reactivity unit (PRU) was measured by VerifyNow
technique as well. CYP2C19, ABCB1, ITGB3, PON1 and P2RY12 allele
were assessed.
RESULTS 236 patients were genotyped and ﬁnished one year follow
up. Clinical endpoints were related to previous heart disease history
(P ¼0.0172), stroke (P ¼0.0483) and diabetes (P ¼0.0474). High
treatment on platelet reactivity (HTPR) were frequent in old age
(P ¼0.0187), male gender (P ¼0.0159), hypertension (P ¼0.0334), heart
disease history (P ¼0.0484) and chronic renal failure (CRF)
(P ¼0.0398). More mutant alleles were found in CYP2C19*2,
CYP2C19*17 and P2RY12 polymorphism (P <0.0001, P ¼0.0025 and
P ¼0.0021, respectively). Patients carrying these three alleles man-
ifested HTPR (P ¼0.00021, 0.00255 and 0.00848, respectively).
However, there was no more cardiovascular deaths in endpoint pa-
tient (for CYP2C19*2 P ¼0.886, for CYP2C19*17 and P2Y12 P ¼1.0).
CONCLUSIONS Clopidogrel-related gene polymorphism are related to
decreasing platelet reactivity after clopidogrel maintaining dose,
increasing major adverse cardiovascular events, without effect on
cardiovascular death.
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Lipoprotein-associated phospholipase A2 and Multi-vessel Disease Predict
the Progression of Nonculprit Lesions in Patients with Acute Coronary
Syndrome After Percutaneous Coronary Intervention
Rui Zhang, Haichu Yu
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OBJECTIVES To elucidate the association of Lipoprotein-associated
phospholipase A2 (Lp-PLA2) activity with progression of nonculprit
lesions undergoing percutaneous coronary intervention (PCI) in pa-
tients with Acute Coronary Syndrome (ACS).
METHODS Our study was comprised 468 Chinese patients with ACS
who treated with PCI from January 2008 to January 2011 in Afﬁliated
Hospital of Qingdao University. All patients were divided into two
groups according to the progression of nonculprit lesions after PCI.
The progressive group was consisted of 152 patients while the
nonprogressive group was consisted of 316 patients. All patients
completed a questionnaire on present condition, family and medical
histories of cardiovascular risk factors and complications, and the
results of coronary angiography. Furthermore, fasting blood samplewas collected from each patient before and after PCI 24 hours to
determine Lp-PLA2 activity.
RESULTS ① The proportion of multi-vessel disease was signiﬁcantly
higher inprogressive group than those in nonprogressive group (P<0.05).
②Compared with nonprogressive group, the mean level of Lp-PLA2 ac-
tivity of progressive group before and after PCI 24 hours were signiﬁ-
cantly higher, and the level of Lp-PLA2 activity after PCI was higher than
before in all patients (12.376.27 nmol/min/ml vs 8.923.16nmol/min/
ml), (21.435.28 nmol/min/ml vs 14.864.18 nmol/min/ml, P<0.05).
CONCLUSIONS Lp-PLA2 activity and multi-vessel disease may predict
the progression of nonculprit lesions after PCI.
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Impacts of Anticoagulation with Bivalirudin versus Low Molecular Weight
Heparin on Thrombopenia during IABP Therapy
Yuan Wang, Hua Xiao, Jinxia Zhang, Zhihua Gong, Dingcheng Xiang
Guangzhou military general hospital
OBJECTIVES Comparing the impacts of low molecular weight heparin
and bivalirudin on blood platelet counts as well as the level of anti-
body of platelet factor 4 heparin-dependent antibodies (H-PF4 IgG)
during IABP therapy.
METHODS This pilot study was designed to totally enroll 60 patients
of AMI complicated cardiac shock who underwent PPCI and IABP
procedure (during or after PPCI). Enoxaparin or bivalirudin were
respectively used as anticoagulation drugs in the heparin group and
the bivalirudin group during IABP therapy after PPCI. Intravenous
blood samples were collected at different time, including before IABP
procedure, at 2 hours, every 24 hours after IABP implantation and
until 72 hours after IABP withdrawn, to measure platelets related
indices, red blood cell related indices, hemolysis related indices and
antibody of H-PF4 IgG. Bone marrow smear to discover the prolifer-
ation status if patients signed informed consent to undergo bone
marrow puncture after IABP withdrawn.
RESULTS The average IABP courses were not signiﬁcantly different be-
tween the heparin group and the bivalirudin group [(4.451.50) day versus
(4.401.47) day, P ¼0.891]. Thrombopenia was developed in 13 patients in
the research, and the incidence of thrombocytopenia was 25%. The general
tendency of platelet changes in the two groups showed that the count went
down rapidly after implantation of IABP and then went slightly up slowly
until the withdrawn of IABP. Once withdrawing IABP, platelet count rose
rapidly and even surpassed the baseline level. The decrease of platelet
number was remarkably smaller in bivalirudin group than in heparin group
(P¼0.043),but therewerenosigniﬁcantdifferencesbetweenthetwogroups
whencomparingat the same timepoints ( P>0.05).Thenumberof redblood
cells, hemoglobinquantitativeandhemotocrit of amplitudeofchangeswere
greater in the heparin group than in bivalirudin group (P < 0.05), and the
basic level of total bilirubin andunconjugated bilirubinweremuchhigher in
the heparin group than in the bivalirudin group (P <0.05). Before implan-
tationof IABP, therewasno signiﬁcantdifferencebetweenthe twogroups in
the level of antibody to H-PF4 IgG (P>0.05). However, the level of antibody
toH-PF4 IgGwasmuchhigher in theheparingroup than inbivalirudingroup
(P¼0.043). and the increase amplitude of antibody toH-PF4 IgGwas greater
in the heparin group than in the bivalirudin group (P ¼0.048).
CONCLUSIONS 1. Platelets number went down rapidly after implan-
tation of IABP and got to the lowest level at the 3rd day, then regained
slowly and got back or even surpassed to the baseline after the
withdrawn of IABP.
2. Mechanical rupture of platelets was the major mechanism of
thrombopenia during IABP therapy when heparin-induced-thrombo-
penia also played an very important role in it.
3. Compared with low molecular weight heparin, bivalirudin
showed a potential to reduce the incidence of thrombopenia while
used as a anticoagulation during IABP therapy.
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OBJECTIVES The law of onset time was very important to prognostic
of patients with acute myocardial infarction. This study investigated
